The long-term goal of the Gladdy Lab Research Program is to develop functional genomics platforms that allow us to better understand sarcoma biology so that we can translate this knowledge into more effective treatments for our patients. Since joining the Lunenfeld-Tanenbaum Research Institute as an Associate Researcher in July 2008, Dr. Gladdy has established an independent laboratory that has focused on Translational Sarcoma Research. She is a full member in the Institute of Medical Science at the University of Toronto.
Dr. Gladdy’s clinical expertise is in the surgical management of soft tissue sarcoma. She is a member of the Toronto Sarcoma Program, which is the Centre of Excellence for Sarcoma Care in Canada and is affiliated with the Princess Margaret Cancer Centre, Mount Sinai Hospital, and the Hospital for Sick Children at the University of Toronto. In addition to having a translational research lab, Dr. Gladdy is part of an active clinical research group that is interested in advancing clinical care through engaging in clinical trials and improving quality of life in sarcoma patients.
Dr. Gladdy is the founder of the Toronto International Sarcoma Symposium (TISS), which was started in 2014 as a biannual Sarcoma CME event that also focused on patient advocacy. TISS provides an opportunity for knowledge translation, faculty networking with international experts and trainee focused tumor boards. She is also on the Medical Advisory Board for Desmoid Tumour Foundation of Canada and a member of the Executive Committee of the National LeioMyoSarcoma Foundation.
Role PI: CIHR, C17 Research Network funding-Round 3-Rhabdomyosarcoma, James Hammond Research Fund for Rhabdomyosarcoma; Panov Program, Sinai Health System; Kristen Ann Carr, Clinical Investigator Award, Society of Surgical Oncology (SSO); The Wilson Sarcoma Research Fund, Princess Margaret Cancer Foundation; The Carlo Fidani Foundation, MSH, LTRI
Role CPI: Innovation Grant, PMH; C17-Children’s Cancer and Blood Disorders-Round 21; Race to Cure Sarcoma Research Award, Sarcoma Foundation of America; Clinical Proteomic Tumor Analysis Consortium, CPTAC (NIH).
Study Chair: Canadian Clinical Trials Group (CCTG) for EORTC-STBSG Study 1809 (STRASS2)
Co-Chair, Sarcoma Disease Site Group, CCTG
We thank all of our agency sponsors and donors for their continued support.